FIELD: medicine.
SUBSTANCE: there is disclosed application of glycosaminoglycan fraction of apparent molecular weight 2400 (±200)D depolymerised from glycosaminoglycan chosen from heparan sulphate and heparin for preparation of pharmaceutical compositions for treating the emotional insanities chosen from depressive disorder, qualm, anxiety neurosis, agitation, mental confusion. Additionally there is disclosed emotional insanity treatment method with no excitory influence depressing effect on central nervous system.
EFFECT: it is revealed that the claimed compounds both reduced emotional reactions and improved exploratory behaviour, ensured better environmental and potential hostility adaptation.
6 cl, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANXIOLYTIC AGENT AND PHARMACEUTICAL COMPOSITION WITH ANXIOLYTIC EFFECT | 1999 |
|
RU2155065C1 |
| PEPTIDE POSSESSING NEUROTROPIC PROPERTIES | 2011 |
|
RU2443712C1 |
| PEPTIDE POSSESSING NEUROTROPIC PROPERTIES | 2011 |
|
RU2443711C1 |
| AGENT FOR TREATMENT OF ANXIETY PATIENTS | 1994 |
|
RU2142274C1 |
| 9-[2-(4-ISOPROPYLPHENOXY)ETHYL]ADENINE POSSESSING ANTIDEPRESSANT AND STRESS-RELIEVING ACTION | 2013 |
|
RU2529817C1 |
| AGENT POSSESSING ANXIOLYTHIC ACTION, ON BASIS OF HYDROGENATED PYRIDO (4,3-b) INDOLES (VERSIONS), PHARMACOLOGICAL AGENT ON ITS BASIS AND WAY OF ITS APPLICATION | 2007 |
|
RU2338533C1 |
| ANTIDEPRESSANT | 2012 |
|
RU2535027C2 |
| METHOD FOR DIVIDING INBRED MICE INTO TYPOLOGICAL GROUPS WITH HIGHER NERVOUS ACTIVITY SPECIFICITY TAKEN INTO CONSIDERATION | 2006 |
|
RU2316057C1 |
| METHOD FOR ASSESSING SPATIAL ORIENTATION AND COGNITIVE DISORDERS IN EXPERIMENTAL ANIMALS | 2012 |
|
RU2551308C2 |
| AGENT POSSESSING ANXIOLYTIC, NOOTROPIC, ANTICONVULSANT, ANTIDEPRESSIVE, CEREBRO-PROTECTING ACTIVITY AND ABILITY TO NORMALISE TRANSFER PROCESSES IN BRAIN SYNAPSES | 2007 |
|
RU2335293C1 |
